141 related articles for article (PubMed ID: 16029381)
1. The impact of catecholamines in patients with or without beta-blockers on the ventricular fibrillation cycle length and ventricular fibrillation cycle length variability.
Min B; Kluger J; Kalus JS; Guertin D; McBride BF; White CM
Ann Noninvasive Electrocardiol; 2005 Jul; 10(3):305-11. PubMed ID: 16029381
[TBL] [Abstract][Full Text] [Related]
2. The impact of catecholamines on defibrillation threshold in patients with implanted cardioverter defibrillators.
Kalus JS; White CM; Caron MF; Guertin D; McBride BF; Kluger J
Pacing Clin Electrophysiol; 2005 Nov; 28(11):1147-56. PubMed ID: 16359280
[TBL] [Abstract][Full Text] [Related]
3. Left ventricular dysfunction is associated with prolonged average ventricular fibrillation cycle length in patients with implantable cardioverter defibrillators.
Fenelon G; Stambler BS; Huvelle E; Brugada P; Stevenson WG;
J Interv Card Electrophysiol; 2002 Dec; 7(3):249-54. PubMed ID: 12510136
[TBL] [Abstract][Full Text] [Related]
4. The mean ventricular fibrillation cycle length: a potentially useful parameter for programming implantable cardioverter defibrillators.
Li H; Easley A; Windle J; Samoil D; Barrington W
Pacing Clin Electrophysiol; 1998 Sep; 21(9):1789-94. PubMed ID: 9744444
[TBL] [Abstract][Full Text] [Related]
5. Increased cycle length variability during ventricular fibrillation: a novel predictor of arrhythmia recurrence.
Yokoshiki H; Kohya T; Sato M; Sasaki K; Yotsukura A; Sakurai M; Kitabatake A
J Electrocardiol; 2003 Apr; 36(2):137-46. PubMed ID: 12764696
[TBL] [Abstract][Full Text] [Related]
6. The impact of carvedilol on the defibrillation threshold.
McBride BF; White CM; Kalus JS; Guertin DC; Clyne CA; Baker WL; Kluger J
Heart Lung; 2008; 37(1):67-71. PubMed ID: 18206529
[TBL] [Abstract][Full Text] [Related]
7. Beta-blocker use and survival in patients with ventricular fibrillation or symptomatic ventricular tachycardia: the Antiarrhythmics Versus Implantable Defibrillators (AVID) trial.
Exner DV; Reiffel JA; Epstein AE; Ledingham R; Reiter MJ; Yao Q; Duff HJ; Follmann D; Schron E; Greene HL; Carlson MD; Brodsky MA; Akiyama T; Baessler C; Anderson JL
J Am Coll Cardiol; 1999 Aug; 34(2):325-33. PubMed ID: 10440140
[TBL] [Abstract][Full Text] [Related]
8. Unsuccessful internal defibrillation in Brugada syndrome: focus on refractoriness and ventricular fibrillation cycle length.
Watanabe H; Chinushi M; Sugiura H; Washizuka T; Komura S; Hosaka Y; Furushima H; Watanabe H; Hayashi J; Aizawa Y
J Cardiovasc Electrophysiol; 2005 Mar; 16(3):262-6. PubMed ID: 15817083
[TBL] [Abstract][Full Text] [Related]
9. Is there a correlation between ventricular fibrillation cycle length and electrophysiological and anatomic properties of the canine left ventricle?
Taneja T; Horvath G; Racker DK; Johnson D; Goldberger J; Kadish A
Am J Physiol Heart Circ Physiol; 2004 Aug; 287(2):H823-32. PubMed ID: 15277204
[TBL] [Abstract][Full Text] [Related]
10. Which strategy is "best" after myocardial infarction? The Beta-blocker Strategy plus Implantable Cardioverter Defibrillator Trial: rationale and study design.
Raviele A; Bongiorni MG; Brignole M; Cappato R; Capucci A; Gaita F; Mangiameli S; Montenero A; Pedretti R; Salerno J; Sermasi S
Am J Cardiol; 1999 Mar; 83(5B):104D-111D. PubMed ID: 10089851
[TBL] [Abstract][Full Text] [Related]
11. Comparison of arrhythmia recurrence in patients presenting with ventricular fibrillation versus ventricular tachycardia in the Antiarrhythmics Versus Implantable Defibrillators (AVID) trial.
Raitt MH; Klein RC; Wyse DG; Wilkoff BL; Beckman K; Epstein AE; Coromilas J; Friedman PL; Martins J; Ledingham RB; Greene HL;
Am J Cardiol; 2003 Apr; 91(7):812-6. PubMed ID: 12667566
[TBL] [Abstract][Full Text] [Related]
12. Ranolazine in High-Risk Patients With Implanted Cardioverter-Defibrillators: The RAID Trial.
Zareba W; Daubert JP; Beck CA; Huang DT; Alexis JD; Brown MW; Pyykkonen K; McNitt S; Oakes D; Feng C; Aktas MK; Ayala-Parades F; Baranchuk A; Dubuc M; Haigney M; Mazur A; McPherson CA; Mitchell LB; Natale A; Piccini JP; Raitt M; Rashtian MY; Schuger C; Winters S; Worley SJ; Ziv O; Moss AJ;
J Am Coll Cardiol; 2018 Aug; 72(6):636-645. PubMed ID: 30071993
[TBL] [Abstract][Full Text] [Related]
13. Propranolol Versus Metoprolol for Treatment of Electrical Storm in Patients With Implantable Cardioverter-Defibrillator.
Chatzidou S; Kontogiannis C; Tsilimigras DI; Georgiopoulos G; Kosmopoulos M; Papadopoulou E; Vasilopoulos G; Rokas S
J Am Coll Cardiol; 2018 May; 71(17):1897-1906. PubMed ID: 29699616
[TBL] [Abstract][Full Text] [Related]
14. Prediction of ventricular arrhythmia events in ischemic heart disease patients with implantable cardioverter-defibrillators.
Feng T; Zhang S; Chen K; Hua W; Ren X
J Mater Sci Mater Med; 2015 Oct; 26(10):240. PubMed ID: 26411436
[TBL] [Abstract][Full Text] [Related]
15. Dofetilide reduces the frequency of ventricular arrhythmias and implantable cardioverter defibrillator therapies.
Baquero GA; Banchs JE; Depalma S; Young SK; Penny-Peterson ED; Samii SM; Wolbrette DL; Naccarelli GV; Gonzalez MD
J Cardiovasc Electrophysiol; 2012 Mar; 23(3):296-301. PubMed ID: 21955243
[TBL] [Abstract][Full Text] [Related]
16. Modification of the circadian pattern of ventricular tachyarrhythmias by beta-blocker therapy.
Behrens S; Ehlers C; Brüggemann T; Ziss W; Dissmann R; Galecka M; Willich SN; Andresen D
Clin Cardiol; 1997 Mar; 20(3):253-7. PubMed ID: 9068912
[TBL] [Abstract][Full Text] [Related]
17. Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial.
Connolly SJ; Dorian P; Roberts RS; Gent M; Bailin S; Fain ES; Thorpe K; Champagne J; Talajic M; Coutu B; Gronefeld GC; Hohnloser SH;
JAMA; 2006 Jan; 295(2):165-71. PubMed ID: 16403928
[TBL] [Abstract][Full Text] [Related]
18. Short-acting beta-adrenergic antagonist esmolol given at reperfusion improves survival after prolonged ventricular fibrillation.
Killingsworth CR; Wei CC; Dell'Italia LJ; Ardell JL; Kingsley MA; Smith WM; Ideker RE; Walcott GP
Circulation; 2004 May; 109(20):2469-74. PubMed ID: 15123529
[TBL] [Abstract][Full Text] [Related]
19. Absence of a morning peak in ventricular tachycardia and fibrillation events in nonischemic heart disease: analysis of therapies by implantable cardioverter defibrillators.
Taneda K; Aizawa Y;
Pacing Clin Electrophysiol; 2001 Nov; 24(11):1602-6. PubMed ID: 11816628
[TBL] [Abstract][Full Text] [Related]
20. Fish oil supplementation and risk of ventricular tachycardia and ventricular fibrillation in patients with implantable defibrillators: a randomized controlled trial.
Raitt MH; Connor WE; Morris C; Kron J; Halperin B; Chugh SS; McClelland J; Cook J; MacMurdy K; Swenson R; Connor SL; Gerhard G; Kraemer DF; Oseran D; Marchant C; Calhoun D; Shnider R; McAnulty J
JAMA; 2005 Jun; 293(23):2884-91. PubMed ID: 15956633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
